Background: Risankizumab (anti–IL-23 p19) is an established therapy for moderate-to-severe psoriasis, with strong trial efficacy and growing real-world evidence. However, long-duration outcomes and treatment-spacing patterns from the Gulf region remain limited. Objective: To evaluate long-term effectiveness, safety, and treatment patterns—including extended-interval dosing—of Risankizumab in a real-world tertiary center. Methods: Single-center retrospective cohort of adults treated with Risankizumab between January 2020 and January 2025. Primary outcome: Psoriasis Area and Severity Index (PASI) 100 on last visit. Secondary outcomes: changes in Psoriasis Area and Severity Index (PASI), body surface area (BSA), and Dermatology Life Quality Index (DLQI) and Nail Psoriasis Severity Index (NAPSI); adverse events; treatment persistence and dosing intervals. Non-parametric tests were used; predictors of PASI 100 were explored with multivariable logistic regression. Results: We included 144 patients (mean age 39.3± 14.9 years; 55.6% male; mean BMI 29.0± 6.5). At last visit, 61.1% achieved PASI 100. Mean scores improved from baseline to last visit: PASI 7.24→ 0.34, BSA 9.81%→ 0.26%, DLQI 7.64→ 0.68, NAPSI 9.56→ 2.94 (all p< 0.001). Adverse events were infrequent (3.5%), all mild; no major adverse cardiovascular events or deaths occurred. A single case of lung cancer was reported and considered unlikely to be treatment related. A quarter of patients transitioned to extended intervals (most commonly every 4– 6 months), with the majority maintaining disease control and relapse occurring infrequently and only after ≥ 6 months. Longer treatment duration and maintenance of standard dosing frequency were associated with achieving PASI 100, while positive family history was associated with lower odds of complete clearance. Conclusion: In routine practice, Risankizumab achieved high complete-clearance rates with excellent tolerability over ~31 months’ mean exposure. Extended-interval dosing was feasible in selected stable responders. These findings align with trial durability and regional registry signals and support individualized long-term strategies.